A subject-level analysis pooling 91 placebo-controlled trials involving nearly 108,000 participants found no increased risk of suicidal ideation or behavior with GLP-1 receptor agonists compared with placebo. The finding focuses on an outcome category that has been scrutinized across multiple drug classes and trial programs.